vs

Side-by-side financial comparison of First Seacoast Bancorp, Inc. (FSEA) and Lineage Cell Therapeutics, Inc. (LCTX). Click either name above to swap in a different company.

Lineage Cell Therapeutics, Inc. is the larger business by last-quarter revenue ($6.6M vs $4.0M, roughly 1.6× First Seacoast Bancorp, Inc.). Lineage Cell Therapeutics, Inc. runs the higher net margin — 12.9% vs -2.4%, a 15.3% gap on every dollar of revenue. On growth, Lineage Cell Therapeutics, Inc. posted the faster year-over-year revenue change (130.4% vs 20.6%). First Seacoast Bancorp, Inc. produced more free cash flow last quarter ($329.0K vs $-5.3M). Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs 12.6%).

Sterling Bancorp was an American regional bank holding company that owned Sterling National Bank. It merged into Webster Bank in February 2022.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

FSEA vs LCTX — Head-to-Head

Bigger by revenue
LCTX
LCTX
1.6× larger
LCTX
$6.6M
$4.0M
FSEA
Growing faster (revenue YoY)
LCTX
LCTX
+109.8% gap
LCTX
130.4%
20.6%
FSEA
Higher net margin
LCTX
LCTX
15.3% more per $
LCTX
12.9%
-2.4%
FSEA
More free cash flow
FSEA
FSEA
$5.6M more FCF
FSEA
$329.0K
$-5.3M
LCTX
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
12.6%
FSEA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FSEA
FSEA
LCTX
LCTX
Revenue
$4.0M
$6.6M
Net Profit
$-87.0K
$851.0K
Gross Margin
Operating Margin
-3.1%
-99.1%
Net Margin
-2.4%
12.9%
Revenue YoY
20.6%
130.4%
Net Profit YoY
93.8%
126.0%
EPS (diluted)
$-0.04
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FSEA
FSEA
LCTX
LCTX
Q4 25
$4.0M
$6.6M
Q3 25
$4.0M
$3.7M
Q2 25
$3.9M
$2.8M
Q1 25
$3.5M
$1.5M
Q4 24
$3.4M
$2.9M
Q3 24
$3.3M
$3.8M
Q2 24
$5.9M
$1.4M
Q1 24
$3.2M
$1.4M
Net Profit
FSEA
FSEA
LCTX
LCTX
Q4 25
$-87.0K
$851.0K
Q3 25
$390.0K
$-29.8M
Q2 25
$-545.0K
$-30.5M
Q1 25
$-603.0K
$-4.1M
Q4 24
$-1.4M
$-3.3M
Q3 24
$44.0K
$-3.0M
Q2 24
$2.0M
$-5.8M
Q1 24
$-1.2M
$-6.5M
Gross Margin
FSEA
FSEA
LCTX
LCTX
Q4 25
Q3 25
Q2 25
Q1 25
97.6%
Q4 24
94.6%
Q3 24
99.0%
Q2 24
96.9%
Q1 24
93.2%
Operating Margin
FSEA
FSEA
LCTX
LCTX
Q4 25
-3.1%
-99.1%
Q3 25
-5.2%
-102.9%
Q2 25
-13.7%
-715.4%
Q1 25
-17.9%
-433.1%
Q4 24
-23.5%
-178.2%
Q3 24
-17.8%
-101.6%
Q2 24
35.6%
-416.7%
Q1 24
-24.8%
-461.3%
Net Margin
FSEA
FSEA
LCTX
LCTX
Q4 25
-2.4%
12.9%
Q3 25
9.8%
-809.0%
Q2 25
-14.1%
-1101.8%
Q1 25
-17.1%
-275.6%
Q4 24
-46.9%
-114.1%
Q3 24
1.3%
-80.3%
Q2 24
33.9%
-409.1%
Q1 24
-36.1%
-453.0%
EPS (diluted)
FSEA
FSEA
LCTX
LCTX
Q4 25
$-0.04
$0.00
Q3 25
$0.08
$-0.13
Q2 25
$-0.13
$-0.13
Q1 25
$-0.14
$-0.02
Q4 24
$-0.31
$0.00
Q3 24
$0.01
$-0.02
Q2 24
$0.42
$-0.03
Q1 24
$-0.24
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FSEA
FSEA
LCTX
LCTX
Cash + ST InvestmentsLiquidity on hand
$55.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$63.5M
$44.5M
Total Assets
$599.3M
$112.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FSEA
FSEA
LCTX
LCTX
Q4 25
$55.8M
Q3 25
$40.5M
Q2 25
$42.3M
Q1 25
$47.9M
Q4 24
$47.8M
Q3 24
$32.7M
Q2 24
$38.5M
Q1 24
$43.6M
Stockholders' Equity
FSEA
FSEA
LCTX
LCTX
Q4 25
$63.5M
$44.5M
Q3 25
$63.2M
$22.0M
Q2 25
$60.8M
$48.4M
Q1 25
$61.2M
$79.0M
Q4 24
$62.0M
$78.4M
Q3 24
$65.8M
$66.2M
Q2 24
$64.5M
$68.3M
Q1 24
$64.7M
$72.4M
Total Assets
FSEA
FSEA
LCTX
LCTX
Q4 25
$599.3M
$112.6M
Q3 25
$609.6M
$89.6M
Q2 25
$604.8M
$90.8M
Q1 25
$592.6M
$111.8M
Q4 24
$580.8M
$113.2M
Q3 24
$601.8M
$96.6M
Q2 24
$601.7M
$102.8M
Q1 24
$576.5M
$108.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FSEA
FSEA
LCTX
LCTX
Operating Cash FlowLast quarter
$449.0K
$-4.9M
Free Cash FlowOCF − Capex
$329.0K
$-5.3M
FCF MarginFCF / Revenue
8.1%
-79.9%
Capex IntensityCapex / Revenue
3.0%
6.0%
Cash ConversionOCF / Net Profit
-5.73×
TTM Free Cash FlowTrailing 4 quarters
$1.4M
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FSEA
FSEA
LCTX
LCTX
Q4 25
$449.0K
$-4.9M
Q3 25
$661.0K
$-3.6M
Q2 25
$-151.0K
$-5.5M
Q1 25
$573.0K
$-4.9M
Q4 24
$-2.9M
$-6.3M
Q3 24
$289.0K
$-5.8M
Q2 24
$-1.4M
$-5.2M
Q1 24
$-70.0K
$-5.8M
Free Cash Flow
FSEA
FSEA
LCTX
LCTX
Q4 25
$329.0K
$-5.3M
Q3 25
$640.0K
$-3.6M
Q2 25
$-154.0K
$-5.6M
Q1 25
$542.0K
$-5.0M
Q4 24
$-3.3M
$-6.7M
Q3 24
$264.0K
$-5.9M
Q2 24
$-1.6M
$-5.2M
Q1 24
$-81.0K
$-5.8M
FCF Margin
FSEA
FSEA
LCTX
LCTX
Q4 25
8.1%
-79.9%
Q3 25
16.0%
-98.6%
Q2 25
-4.0%
-200.8%
Q1 25
15.4%
-331.8%
Q4 24
-99.0%
-234.0%
Q3 24
7.9%
-156.1%
Q2 24
-26.5%
-371.2%
Q1 24
-2.5%
-403.1%
Capex Intensity
FSEA
FSEA
LCTX
LCTX
Q4 25
3.0%
6.0%
Q3 25
0.5%
0.3%
Q2 25
0.1%
0.5%
Q1 25
0.9%
6.5%
Q4 24
11.0%
12.7%
Q3 24
0.7%
3.0%
Q2 24
2.8%
3.6%
Q1 24
0.3%
2.6%
Cash Conversion
FSEA
FSEA
LCTX
LCTX
Q4 25
-5.73×
Q3 25
1.69×
Q2 25
Q1 25
Q4 24
Q3 24
6.57×
Q2 24
-0.70×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FSEA
FSEA

Segment breakdown not available.

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

Related Comparisons